Literature DB >> 2494260

Immune responses during human schistosomiasis mansoni. XVI. Idiotypic differences in antibody preparations from patients with different clinical forms of infection.

M A Montesano1, M S Lima, R Correa-Oliveira, G Gazzinelli, D G Colley.   

Abstract

Antibodies were purified from pooled sera from patients with different clinical forms of schistosomiasis mansoni on immunoaffinity columns of schistosome soluble egg Ag (SEA). As previously reported, T lymphocytes in PBMC preparations from schistosomiasis patients (but not control subjects who have never been infected) proliferate when cultured in the presence of certain of these anti-SEA purified antibodies. We now show that PBMC from most patients with chronic schistosomiasis, regardless of the clinical form of their infection, respond to anti-SEA antibodies from sera of asymptomatic (intestinal) or hepatointestinal patients. In stark contrast, none responds to anti-SEA antibodies purified from sera of acute or hepatosplenic patients. All of these multiclonal anti-SEA antibody preparations were active in anti-SEA ELISA assays and gave comparable patterns of reactivity with SEA upon immunoblotting analysis. Immunization of rabbits with some of these anti-SEA antibody preparations, followed by absorption of the rabbit antisera on absorbents of normal Ig, produced specific anti-Id reagents. Use of these reagents in competitive ELISA systems demonstrated that the Id in stimulatory and nonstimulatory anti-SEA antibody preparations differ with regard to the proportion of the serologically defined Id expressed by each. It appears possible to screen patients' plasmas for the presence of shared Id by use of suitable Id/anti-Id competitive ELISA assays. Taken together these data indicate that only certain Id-positive preparations are stimulatory to patients' PBMC, and the expression of these T cell stimulatory, immunoregulatory Id on anti-SEA antibodies correlates with the clinical form of a patient's infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Murine schistosomiasis as a model for human schistosomiasis mansoni: similarities and discrepancies.

Authors:  Rashad A Abdul-Ghani; Azza A Hassan
Journal:  Parasitol Res       Date:  2010-04-06       Impact factor: 2.289

2.  Idiotypic sensitization in utero of children born to mothers with schistosomiasis or Chagas' disease.

Authors:  S M Eloi-Santos; E Novato-Silva; V M Maselli; G Gazzinelli; D G Colley; R Correa-Oliveira
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

3.  Differential Vbeta T-cell receptor usage during chronic experimental schistosomiasis corresponds with distinct pathological presentations.

Authors:  W E Secor; G L Freeman
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Serum osteopontin is a biomarker of severe fibrosis and portal hypertension in human and murine schistosomiasis mansoni.

Authors:  Thiago Almeida Pereira; Wing-Kin Syn; Fausto E L Pereira; José Roberto Lambertucci; William Evan Secor; Anna Mae Diehl
Journal:  Int J Parasitol       Date:  2016-10-10       Impact factor: 3.981

5.  Two distinct pathological syndromes in male CBA/J inbred mice with chronic Schistosoma mansoni infections.

Authors:  G S Henderson; N A Nix; M A Montesano; D Gold; G L Freeman; T L McCurley; D G Colley
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

6.  Idiotypes expressed early in experimental Schistosoma mansoni infections predict clinical outcomes of chronic disease.

Authors:  M Angela Montesano; Daniel G Colley; Margaret T Willard; George L Freeman; W Evan Secor
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

7.  Neonatal idiotypic exposure alters subsequent cytokine, pathology, and survival patterns in experimental Schistosoma mansoni infections.

Authors:  M A Montesano; D G Colley; S Eloi-Santos; G L Freeman; W E Secor
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.